197 related articles for article (PubMed ID: 19706813)
21. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
22. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
23. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
24. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
25. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
[TBL] [Abstract][Full Text] [Related]
26. The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells.
Choi E; Kim Y; Kim K
Yonsei Med J; 2006 Feb; 47(1):55-62. PubMed ID: 16502485
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
28. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
29. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
31. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
Arizono Y; Yoshikawa H; Naganuma H; Hamada Y; Nakajima Y; Tasaka K
Br J Cancer; 2003 Jan; 88(2):298-306. PubMed ID: 12610517
[TBL] [Abstract][Full Text] [Related]
32. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
[TBL] [Abstract][Full Text] [Related]
33. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism.
Pei GT; Wu CW; Lin WW
Biochem Biophys Res Commun; 2010 Jan; 391(2):1274-9. PubMed ID: 20018172
[TBL] [Abstract][Full Text] [Related]
36. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.
Ouyang W; Yang C; Liu Y; Xiong J; Zhang J; Zhong Y; Zhang G; Zhou F; Zhou Y; Xie C
Int J Oncol; 2011 Dec; 39(6):1577-86. PubMed ID: 21769428
[TBL] [Abstract][Full Text] [Related]
37. Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells.
Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
J Orthop Res; 2010 Jun; 28(6):739-45. PubMed ID: 20041491
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
39. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
Fulda S; Küfer MU; Meyer E; van Valen F; Dockhorn-Dworniczak B; Debatin KM
Oncogene; 2001 Sep; 20(41):5865-77. PubMed ID: 11593392
[TBL] [Abstract][Full Text] [Related]
40. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.
Yang X; Merchant MS; Romero ME; Tsokos M; Wexler LH; Kontny U; Mackall CL; Thiele CJ
Cancer Res; 2003 Mar; 63(5):1122-9. PubMed ID: 12615731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
